[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BRPI0314666B8 - composição nutricional ou terapêutica utilizável para o tratamento de mamíferos para aumentar a atividade imune - Google Patents

composição nutricional ou terapêutica utilizável para o tratamento de mamíferos para aumentar a atividade imune

Info

Publication number
BRPI0314666B8
BRPI0314666B8 BRPI0314666A BRPI0314666A BRPI0314666B8 BR PI0314666 B8 BRPI0314666 B8 BR PI0314666B8 BR PI0314666 A BRPI0314666 A BR PI0314666A BR PI0314666 A BRPI0314666 A BR PI0314666A BR PI0314666 B8 BRPI0314666 B8 BR PI0314666B8
Authority
BR
Brazil
Prior art keywords
nutritional
treatment
mammals
therapeutic composition
immune activity
Prior art date
Application number
BRPI0314666A
Other languages
English (en)
Inventor
Crum Albert
Original Assignee
The Proimmune Company
Crum Albert
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Proimmune Company, Crum Albert filed Critical The Proimmune Company
Publication of BRPI0314666B8 publication Critical patent/BRPI0314666B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)

Abstract

"COMPOSIÇÃO NUTRICIONAL OU TERAPÊUTICA UTILIZÁVEL PARA O TRATAMENTO DE MAMÍFEROS PARA AUMENTAR A ATIVIDADE IMUNE E MÉTODO DE TRATAR UM MAMÍFERO PARA AUMENTAR A CONCENTRAÇÃO DE GLUTATIONA NO TECIDO NO REFERIDO MAMÍFERO". As composições nutricionais ou terapêuticas contendo ácido glutâmico, cistina, glicina e um precursor de selênio e métodos para sua utilização para aumentar a síntese de glutationa e assim aumentar o sistema imune são descritos.
BRPI0314666A 2002-09-23 2003-07-11 composição nutricional ou terapêutica utilizável para o tratamento de mamíferos para aumentar a atividade imune BRPI0314666B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/252,957 US6592908B1 (en) 2002-09-23 2002-09-23 Nutritional or therapeutic compositions
PCT/US2003/021739 WO2004026289A1 (en) 2002-09-23 2003-07-11 Nutritional or therapeutic compositions

Publications (1)

Publication Number Publication Date
BRPI0314666B8 true BRPI0314666B8 (pt) 2022-11-22

Family

ID=22958261

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0314666A BRPI0314666B1 (pt) 2002-09-23 2003-07-11 composição nutricional ou terapêutica utilizável para o tratamento de mamíferos para aumentar a atividade imune
BRPI0314666A BRPI0314666B8 (pt) 2002-09-23 2003-07-11 composição nutricional ou terapêutica utilizável para o tratamento de mamíferos para aumentar a atividade imune

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BRPI0314666A BRPI0314666B1 (pt) 2002-09-23 2003-07-11 composição nutricional ou terapêutica utilizável para o tratamento de mamíferos para aumentar a atividade imune

Country Status (8)

Country Link
US (4) US6592908B1 (pt)
EP (2) EP3431080A1 (pt)
JP (2) JP5601745B2 (pt)
AU (2) AU2003253884A1 (pt)
BR (2) BRPI0314666B1 (pt)
CA (1) CA2539567C (pt)
MX (1) MXPA05003227A (pt)
WO (1) WO2004026289A1 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040247709A1 (en) * 2003-06-06 2004-12-09 Pro-Health, Inc. Composition and method for treating upper abdominal pain and cramping
WO2005007223A2 (en) * 2003-07-16 2005-01-27 Sasha John Programmable medical drug delivery systems and methods for delivery of multiple fluids and concentrations
US20050271726A1 (en) * 2004-06-02 2005-12-08 Albert Crum Immune enhancing compositions and methods of use thereof
FR2879074B1 (fr) * 2004-12-15 2007-08-03 Adisseo France Sas Soc Par Act Granules de principe actif hydrophile
US20080095826A1 (en) * 2006-10-24 2008-04-24 Hisayuki Uneyama Method of Increasing Peripheral Blood Lymphocytes
CN103535721B (zh) * 2013-09-27 2016-04-06 美国东方生物技术（香港）有限公司 提高人体内谷胱甘肽浓度的组合物及其制备方法和应用
CN103478718B (zh) * 2013-09-27 2015-10-28 美国东方生物技术（香港）有限公司 提高人体内谷胱甘肽浓度的功能食品及其制备方法
WO2016033183A1 (en) 2014-08-29 2016-03-03 Crum Albert B A method for side effect reduction in the use of statins via physiologically synthesized glutathione
US20160101079A1 (en) * 2014-10-09 2016-04-14 Albert Crum Protective metallothionein analog compounds, their compositions and use thereof in the treatment of pathogenic diseases
AU2017234662A1 (en) * 2016-03-14 2018-10-04 Mitogenetics, Llc Materials and methods for treating hypoxic conditions
JP7084924B2 (ja) 2016-12-21 2022-06-15 ユニリーバー・アイピー・ホールディングス・ベスローテン・ヴェンノーツハップ 難溶性化合物を含むパーソナルケア組成物
CN110099672B (zh) 2016-12-21 2022-05-24 联合利华知识产权控股有限公司 具有氨基酸和烟酰胺化合物的局部皮肤增亮添加剂和组合物
JP7082623B2 (ja) 2016-12-21 2022-06-08 ユニリーバー・アイピー・ホールディングス・ベスローテン・ヴェンノーツハップ シスチンを有するパーソナルケア用組成物
US11260005B2 (en) 2016-12-21 2022-03-01 Conopco, Inc. Personal care compositions with glutathione precursor comprising 4-substituted resorcinols and amino acids
CA3046138A1 (en) * 2016-12-21 2018-06-28 Unilever Plc Personal care compositions with glutathione precursor comprising nicotinamide and amino acids
JP7497296B2 (ja) 2018-05-23 2024-06-10 ユニリーバー・アイピー・ホールディングス・ベスローテン・ヴェンノーツハップ ナノエマルジョン及びその製造方法
JP2023523976A (ja) 2020-04-28 2023-06-08 ユニリーバー・アイピー・ホールディングス・ベスローテン・ヴェンノーツハップ Ｎ，ｎ’－ジアセチル－ｌ－シスチンの製造方法
US20230157939A1 (en) 2020-04-28 2023-05-25 Conopco, Inc., D/B/A Unilever Personal care compositions with enhanced solubility actives
JP2023523225A (ja) 2020-04-28 2023-06-02 ユニリーバー・アイピー・ホールディングス・ベスローテン・ヴェンノーツハップ Ｎ，ｎ’－ジアセチルシスチンを含有する安定化化粧品組成物
WO2021219377A1 (en) 2020-04-28 2021-11-04 Unilever Ip Holdings B.V. Process of making n,n-diacetyl-l-cystine disodium salt from cystine and acetyl chloride in methanol in the presence of sodium hydroxide
CN116669693A (zh) * 2020-12-28 2023-08-29 盛势达（瑞士）有限公司 口腔用组合物
AU2023336819A1 (en) 2022-09-08 2025-04-03 The Proimmune Company, Llc Compositions to increase glutathione levels and processes for making the same
US20240108695A1 (en) * 2022-09-21 2024-04-04 Lile Method Research, Llc Compositions and methods for preventing and/or treating tuberculosis and mrsa

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288497A (en) 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
JPH0667833B2 (ja) * 1985-11-28 1994-08-31 雪印乳業株式会社 経腸栄養剤
US4885157A (en) * 1987-02-13 1989-12-05 Fiaschetti Mary G Dermal cosmetic composition and applications therefor
US5888552A (en) * 1988-04-29 1999-03-30 Immunotec Research Corporation Ltd. Anti-cancer therapeutic compositions containing whey protein concentrate
FI892006A7 (fi) * 1988-04-29 1989-10-30 Phil Gold Laktalbumiini ruoan lisäaineena
US5576351A (en) * 1989-12-29 1996-11-19 Mcgaw, Inc. Use of arginine as an immunostimulator
AU679020B2 (en) * 1992-12-23 1997-06-19 Abbott Laboratories Medical foods for the nutritional support of infant/toddler metabolic diseases
JP3013871B2 (ja) * 1993-10-02 2000-02-28 日本水産株式会社 海産養殖魚の免疫活性賦活化方法
GB9416921D0 (en) * 1994-08-22 1994-10-12 Conway Gitta C A nutritional preparation
US5719133A (en) * 1994-09-21 1998-02-17 Novartis Nutrition Ag Adolescent dietary composition
RU2096034C1 (ru) * 1994-11-30 1997-11-20 Общество с ограниченной ответственностью "Медицинский научно-производственный комплекс "БИОТИКИ" Фармацевтическая композиция, индуцирующая биосинтез глутатиона, активность глутатионтрансферазы и оказывающая антитоксическое, радиопротекторное и антигипоксическое действие, и способы лечения, профилактики и защиты с ее использованием
AU4751697A (en) * 1996-10-10 1998-05-05 Douglas Danner Animal cell culture media comprising plant-derived nutrients
JPH1149696A (ja) * 1997-03-21 1999-02-23 Shiseido Co Ltd 紫外線皮膚免疫機能低下防止用免疫賦活剤
JPH11292737A (ja) * 1998-02-16 1999-10-26 Shiseido Co Ltd 免疫賦活剤
DE69930746T2 (de) * 1998-06-10 2007-03-15 Crum, Albert B. Vorbeugender und therapeutischer nahrungsmittelzusatz zur schaffung/erhaltung einer die gesundheit schützenden darmmikroflora und zur stärkung des immunsystems
JP2000245358A (ja) * 1999-02-25 2000-09-12 Kohjin Co Ltd サケ・マス類の養殖用飼料及び養殖方法
AU6768200A (en) * 1999-08-11 2001-03-05 Proimmune Company L.L.C., The Nutritious compositions and food components
GB0009056D0 (en) * 2000-04-12 2000-05-31 Nestle Sa Composition comprising free amino acids
US6495170B1 (en) * 2000-08-16 2002-12-17 N. V. Nutricia Method of increasing the presence of glutathione in cells

Also Published As

Publication number Publication date
JP2006502182A (ja) 2006-01-19
EP3431080A1 (en) 2019-01-23
WO2004026289A1 (en) 2004-04-01
USRE39734E1 (en) 2007-07-17
EP1556023A4 (en) 2010-06-02
BR0314666A (pt) 2005-08-02
MXPA05003227A (es) 2005-08-18
CA2539567A1 (en) 2004-04-01
USRE42645E1 (en) 2011-08-23
BRPI0314666B1 (pt) 2015-12-29
EP1556023B1 (en) 2018-10-17
AU2003253884A1 (en) 2004-04-08
JP5846822B2 (ja) 2016-01-20
AU2010201136B2 (en) 2013-01-24
JP2012017336A (ja) 2012-01-26
AU2010201136A1 (en) 2010-04-15
US20120029082A1 (en) 2012-02-02
JP5601745B2 (ja) 2014-10-08
CA2539567C (en) 2013-09-24
US6592908B1 (en) 2003-07-15
EP1556023A1 (en) 2005-07-27

Similar Documents

Publication Publication Date Title
BRPI0314666B8 (pt) composição nutricional ou terapêutica utilizável para o tratamento de mamíferos para aumentar a atividade imune
WO2004043361A3 (en) Compositions and methods for the treatment of natural killer cell related diseases
WO2004024097A8 (en) Compositions and methods for the treatment of immune related diseases
WO2004047728A3 (en) Compositions and methods for the treatment of immune related diseases
WO2004039956A3 (en) Compositions and methods for the treatment of immune related diseases
NO20045521L (no) Diarylureaderivater anvendelige for behandling av proteinkinaseavhengige sykdommer
AU2003217055A1 (en) Protein for use in hypoxia related conditions
ATE262348T1 (de) Mittel zur verabreichung von antigenen
WO2004024068A3 (en) Novel composition and methods for the treatment of immune related diseases
CY1108689T1 (el) Ολιγοπεπτιδια για την ελαττωση αυξημενης συγκεντρωσεως της ουριας στο αιμα
BR0315688A (pt) Compostos, composições farmacêuticas e seus usos no tratamento ou prevenção de doenças ou condições de proliferação celular metabólicas
BRPI0411241A (pt) agentes terapêuticos úteis para o tratamento de dor
EA200500169A1 (ru) Замещенные производные 1,3-дифенилпроп-2-ен-1-она, получение и применение
ATE457726T1 (de) Nahrungs- oder pharmazeutische zusammensetzungen zur erhöhung der creatin-antwort von organismen
EA200401111A1 (ru) Биполярные соли транс-каротиноидов и их применение
BRPI0410861A (pt) métodos e composições para a produção de aminoácidos
DE602004017871D1 (de) Zubereitungen zur behandlung von arthritischen erscheinungen
BR9909234A (pt) Método para fornecimento de glutamina
BRPI0720230A2 (pt) Uso de uma formulação nutricional oralmente administrável, formulação nutricional, método para tratar um distúrbio desenvolvimental penetrante, e, composição
BR0308713A (pt) Co-esférula de dha e alecrim, e métodos de uso
CY1113871T1 (el) Διαδικασια παρασκευης γκαμπαπεντινης
EA200501069A1 (ru) Состав для местного применения и способы обработки старческой или повреждённой воздействием окружающей среды кожи
MA30139B1 (fr) Preparation de gamma-aminoacides ayant une affinite pour la proteine alpha-2-delta.
WO2004024072A3 (en) Novel compositions and methods for the treatment of immune related diseases
PT1276763E (pt) Proteinas anti-congelantes sua producao e utilizacao

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: ALBERT CRUM (US)

Free format text: TRANSFERIDO DE: THE PROIMMUNE COMPANY

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: "PARA: INT. CL. A61K 31/095, 33/04, 31/197, 31/198

Ipc: A61K 31/095 (2011.01), A61K 33/04 (2011.01), A61K

Free format text: PARA: INT. CL. A61K 31/095, 33/04, 31/197, 31/198; A61P 37/00

Ipc: A61K 31/095 (2011.01), A61K 33/04 (2011.01), A61K

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/12/2015, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/07/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B15V Prolongation of time limit allowed
B22E Other requirements [chapter 22.5 patent gazette]

Free format text: FORMULADA EXIGENCIA PARA ADEQUACAO OU CUMPRIMENTO DE DISPOSICOES LEGAIS NO PRAZO DE 60 (SESSENTA) DIAS DESTA DATA.

B16B Notification of grant cancelled [chapter 16.2 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 16.3 NA RPI NO 2629 DE 25/05/2021 POR TER SIDO INDEVIDA.